Kaitlyn Bennett, NP
Family · Scottsboro, ALNPI 1154910123
Payments from drug & device makers
Across 113 payments — averaging $16.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$277
- AbbVie$236
- Lilly USA, LLC$233
- Dexcom, Inc.$143
- Biohaven Pharmaceutical Holding Company Ltd.$124
- Pfizer$98
- plus $759 from 17 others
What the payments were for
- Food & beverage$1,869100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $277 |
| AbbVie | 15 | $236 |
| Lilly USA, LLC | 13 | $233 |
| Dexcom, Inc. | 7 | $143 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $124 |
| Pfizer | 5 | $98 |
| Daiichi Sankyo Inc. | 6 | $96 |
| Boehringer Ingelheim | 5 | $94 |
| Amgen | 5 | $82 |
| Merck | 5 | $82 |
| AstraZeneca | 4 | $64 |
| Sanofi-aventis U.S. LLC | 3 | $44 |
| Medline Industries LP | 1 | $39 |
| Mannkind Corporation | 2 | $37 |
| Corium, LLC | 6 | $36 |
| Abbott | 2 | $31 |
| Arbor Pharmaceuticals, Inc. | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Optinose US, Inc. | 1 | $29 |
| Redhill Biopharma Inc. | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
How this compares
$1,869 in reported general payments places this provider in the 75th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ipratropium Bromide | 83 | $2,877 |
| Montelukast Sodium | 111 | $1,959 |
| Fluticasone Propionate | 152 | $1,947 |
| Mometasone Furoate | 58 | $1,866 |
| Levocetirizine Dihydrochloride | 106 | $1,147 |
| Ofloxacin | 22 | $783 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $331 |
| Mupirocin | 28 | $285 |
| Omeprazole | 26 | $226 |
| Famotidine | 25 | $211 |
| Doxycycline Hyclate | 29 | $180 |
| Pantoprazole Sodium | 20 | $143 |
Paid to pharmacies, not to this prescriber.
Other family in Scottsboro
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.